Table 1.
Characteristics, Exposures, and Risk Behaviors Among 127 Injection Drug Users With Acute Hepatitis C Virus Infection
| Baseline Characteristic | Chronic HCV No. (%) | Cleared or Intermittent HCV Infection (n = 43),a No. (%)b |
|||
|---|---|---|---|---|---|
| Total | Persistent Cleared | Reinfection | Intercalation | ||
| Overall | 83 | 44c | 36 (83.7) | 4 (9.3) | 3 (7.0) |
| Age | |||||
| ≤22 y | 40 (48.2) | 15 (34.1) | 13 (86.7) | 1 (13.3) | 0 (0) |
| >22 y | 43 (51.8) | 29 (65.9) | 23 (79.38) | 3 (10.3) | 3 (10.3) |
| Race/ethnicity | |||||
| White | 62 (74.7) | 36 (81.8) | 30 (85.7) | 3 (8.6) | 2 (5.7) |
| Nonwhite | 21 (25.3) | 8 (18.2) | 6 (75.0) | 1 (12.5) | 1 (12.5) |
| Sex | |||||
| Male | 57 (68.7) | 20 (45.5) | 14 (73.7) | 3 (15.8) | 2 (10.5) |
| Female | 26 (31.3) | 24 (54.5) | 22 (91.7) | 1 (4.2) | 1 (4.2) |
| HCV genotype, primary infection | |||||
| 1 | 41 (49.4) | 17 (63.0) | 13 (76.5) | 2 (11.8) | 2 (11.8) |
| 2 | 8 (9.6) | 3 (11.1) | 1 (33.3) | 1 (33.3) | 1 (33.3) |
| 3 | 29 (34.9) | 4 (14.8) | 2 (66.7) | 1 (33.3) | 0 (0 (0) |
| 4 | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Not available | 4 (4.8) | 3 (11.1) | 3 (100) | 0 (0) | 0 (0) |
| Peak HCV viremia during primary infection, log IU/mL, median (IQR) | 6.3 (5.4–6.9) | 5.8 (2.7–7.2) | 6.0 (3.0–7.2) | 0.8 (0.8–0.8)d | 7.4 (7.4–7.4) |
| Peak ALT during primary infection, U/L, median (IQR) | 138 (75–250) | 39 (20–195) | 66 (33–219) | 20 (20–20) | 97 (15–179) |
Data are presented as No. (%) unless otherwise specified.
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; IQR, interquartile range.
a Reinfection status for 1 case could not be determined and is excluded from 3 right-hand columns.
b Percentages are estimated from the number of cleared infections by strata.
c N = 44 including n = 26 incident HCV clearers with 2 or more visits after HCV infection and n = 18 HCV resolved at baseline.
d Reinfection vs cleared infection: P = .10.